Skip to main content
AAgilent Technologies, Inc.Buy Wait5.4·$150.86+0.59%

Agilent Technologies (A) Q2 2026 earnings — TrendMatrix coverage

BEAT+9.0% vs estimateEPS $1.62 vs $1.49 estVerdict HoldSell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.62
Estimate
$1.49
Surprise
+9.0%
Score at report (before → after)
5.35.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Agilent Technologies (A) beat the $1.49 estimate with diluted EPS of $1.62 — a clear 9.0% upside surprise. TrendMatrix's engine moved from Hold (5.3/10) to Sell at 5.4/10 after the report.

Current read · as of 2026-09-06

Where TrendMatrix's rating stands now

TrendMatrix currently rates A Buy (Wait) at 5.4/10.

3 of the last 4 quarters beat the estimate; this quarter's +9.0% surprise compares with a +3.6% four-quarter average. Next scheduled report: 2026-11-25.

What supports the rating

  • V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Thin upside margin: 4.7%
  • Negative momentum
  • Momentum score 3.8/10 — below 4.5 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$150.86
Entry target
$145.68
Price target
$157.91
Stop
$141.09
Upside to target
+4.7%
Reward-to-risk
0.7:1

The stock trades at 29.6× trailing but 22.3× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.

Healthcare context

A at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$42.54B
P/E (fwd)
22.3
P/E (ttm)
29.6
52-week range
$108.35$163.75
Off 52-week high
7.9%
RSI (14)
54
Volume vs avg
0.79×
Score today
5.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks A Earnings Q2 2026 earnings